Articles & Video
REPORT: COVID-19 Response in Cell & Gene Therapy Manufacturing 2021
This exclusive report uncovers the major changes in the cell and gene therapy sector during the COVID-19 pandemic.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
COVID-19 has benefited investment in the cell and gene therapy sector, say 78% of industry professionals
We investigate how the COVID-19 pandemic has transformed business, finance and investment in cell and gene therapies.
Life Sciences Survey: COVID-19 Impacts One Year On
Take part in our industry survey on the impacts of COVID-19 on the life sciences one year on to get exclusive early access to the final report.
63% of cell and gene therapy professionals changed their supply chain strategies due to COVID-19
We examine new data on the challenges in cell and gene therapy supply chain and manufacturing as a result of the COVID-19 pandemic.
Personalized Medicine: Neoantigen Cancer Vaccines and T Cell Therapy
We look at precision antigen selection carried out with a personalized immune response profiling platform, demonstrated at TIDES: Oligonucleotide and Peptide Therapeutics.
REPORT: Diversity, Equity and Inclusion in the Life Sciences 2021
Explore the Diversity, Equity and Inclusion in the Life Sciences 2021 report based on an exclusive study of 483 industry professionals.
Advancing Gene Therapies: Evaluating Immunogenicity and its Impact on Therapeutic Potential
What are the considerations for selecting the best immunogenicity assay?
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
Post-event Report: Cell & Gene Therapy Bioprocessing & Commercialization 2020
We review the key highlights from the virtual conference, including analysis of the hottest sessions by BioProcess International magazine.
Pharma’s role in maintaining cancer mortality progress during COVID-19
COVID-19 is threatening the progress made in reducing cancer mortality. Pharma has a pivotal role to play in helping patients and providers navigate the new reality of cancer treatment during the pandemic, and beyond.
BioProcess International Fall Digital Week 2020
We explore the agenda for the upcoming BioProcess International Fall Digital Week 2020.
BioProcess International 2020 Post-Event Report
Explore the highlights of the BioProcess International 2020 virtual conference in the post-event round-up.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
When to outsource manufacturing? Advice for cell and gene therapy developers
What scenarios could determine when is best to outsource manufacturing of cell and gene therapies to a CDMO?
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Vector manufacturing for cell and gene therapies: how should current platforms be changed?
What do we need from vector manufacturing platforms to deliver commercial scale therapies? We look at responses from industry insiders.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Women in Pharma: 44% of pharma professionals think that women are under represented in their organization
44% of pharma professionals think that women are under represented in their organization according to new data from an Informa Connect Life Sciences study. Here we deep dive into the data.